Erlotinib Completed Phase 2 Trials for Head and Neck Carcinoma Prevention

IndicationsStatusPurposePhase
CompletedPrevention2
clinicaltrials.gov IdentifierTitleDrugs
NCT00570232UAB 0718 - Phase II Trial to Assess Target Oral Therapy as Adjuvant Chemoprevention in High-Risk Head and Neck Cancer